Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 7/20 | 0.37 |
| ▸ | IDO1 | P14902 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885090 | 0.77 | LMNA (0.41) | LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7029091 | 0.74 | IDH1 (0.32) | IDH1IDH2ALDH1A1 | |
| SCHEMBL6081804 | 0.74 | CRHR1 (0.41) | SOS1 | |
| SCHEMBL21159495 | 0.73 | CHRM2 (0.39) | IDO1LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4737704 | 0.73 | PTGER4 (0.60) | PTGER4 | |
| SCHEMBL12138409 | 0.72 | ALDH1A1 (0.44) | LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28908267 | 0.72 | LMNA (0.38) | IDH1IDH2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6223842 | 0.71 | ADORA2A (0.45) | LMNAALDH1A1MAPTADORA2A | |
| SCHEMBL6223839 | 0.71 | ADORA2A (0.45) | LMNAALDH1A1MAPTADORA2A | |
| SCHEMBL28908277 | 0.71 | KMT2A (0.53) | LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642230-B2 | Administering novel compounds which bind to corticotropin releasing factor receptors, thereby altering anxiogenic effects of CRF secretion | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-06-19 | — | — | US | disclosed |
| US-6362180-B1 | ANTAGONIST TO CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-6143743-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | CRH, CRHR1, CRHR2 | IDH1 3332/4885IDH2 2551/4885BCL6 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.